Novanta ( (NOVT) ) has released its Q2 earnings. Here is a breakdown of the information Novanta presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Novanta Inc., a prominent technology partner for medical and advanced technology equipment manufacturers, has released its financial results for the second quarter of 2025, showcasing its role in the precision medicine, manufacturing, robotics, and automation sectors.
In the second quarter of 2025, Novanta reported a 2% increase in GAAP revenue, reaching $241 million, with a GAAP net income of $4.5 million and a diluted earnings per share of $0.12. The company also achieved an adjusted EBITDA of $52 million and an adjusted EPS of $0.76, reflecting its robust performance amidst challenging economic conditions.
Key highlights from the report include a 10% growth in bookings and a book-to-bill ratio of 1.02, indicating a strengthening outlook. Novanta’s strategic focus on high-growth markets was evident with mid-teens revenue growth in its Advanced Surgery and Robotics & Automation businesses. The company also secured significant design wins in the medical device and warehouse robotics sectors, aligning with its long-term growth strategy.
Despite a decrease in GAAP operating income and net income compared to the previous year, Novanta’s adjusted financial metrics demonstrated resilience. The company continues to leverage its Novanta Growth System to drive new product sales, targeting $50 million in new product sales for the year.
Looking ahead, Novanta anticipates sequential revenue and profit growth, driven by its innovation pipeline and strong customer demand in growth markets. The company expects full-year 2025 GAAP revenue between $970 million and $985 million, with adjusted EBITDA ranging from $225 million to $230 million.